Biologics selected as distributor for Pfizer's Besponsa

Besponsa was approved as an antibody-drug conjugated to calicheamicin.
Besponsa was approved as an antibody-drug conjugated to calicheamicin. | File photo

Biologics Inc., an oncology pharmacy services company under the McKesson Specialty Health umbrella, recently announced that Pfizer selected it to distribute Besponsa, a new IV therapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

Besponsa was approved by the U.S. Food and Drug Administration as an antibody-drug conjugated to calicheamicin. It targets the marker CD22 which, according to Biologics, is expressed in more than 90 percent of patients with B-cell ALL.

“Clinical trial results for BESPONSA are very impressive, demonstrating significant clinical benefits,” Brandon Tom, vice president of Biopharma Services at McKesson Specialty Health, said in a statement. “We look forward to being a specialty pharmacy provider for this exciting new therapy that could potentially play a role in changing the treatment landscape for ALL.”

Biologics is part of McKesson Specialty Health, which is a division of McKesson Corp. The specialty health group works to empower the community patient care delivery system through community-based advancement of science, technology and quality of care.

Want to get notified whenever we write about McKesson, Inc. ?
Next time we write about McKesson, Inc., we'll email you a link to the story. You may edit your settings or unsubscribe at any time.
Organizations in this story

McKesson, Inc. 1 Post St San Francisco, CA - 94104